Navigation Links
Transposagen Issued Two Key U.S. Patents
Date:11/1/2013

LEXINGTON, Ky., Nov. 1, 2013 /PRNewswire-iReach/ -- Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced today the issuing of Patent No. 8,399,643 entitled, "Nucleic Acids Encoding Hyperactive PiggyBac Transposases" on March 19th and Patent No. 8,558,055 entitled, "A Genetically Modified Rat Comprising a Cytokine Gene Disruption and Exhibiting a Greater Susceptibility to a Cytokine-Mediated Autoimmune and/or Inflammatory Disease" on October 15th. The patents have terms extending through 2030.

(Photo: http://photos.prnewswire.com/prnh/20131101/MN08740)

The piggyBacTM DNA transposon is the most efficient and safe technology for delivering DNA stably into the genome of animals and is being used in biomedical, agricultural and human therapeutic applications. Transposagen tested over 2 million variations of the piggyBacTM transposase enzyme and discovered versions of the enzyme that are more than 10 times more active than the version found in nature. The piggyBacTM technology is also a critical component of Footprint-FreeTM Gene Editing, one of the only commercially available methods to edit as little as a single nucleotide in the genome of nearly any organism. "The new 'super piggyBacTM vectors and PB-GoldTM kit, will allow researchers to perform stable transfection for the same cost and on the same timeline as transient transfection." said Jack Crawford, M.Sc., Transposagen's Director of Sales and Marketing.

The more recent patent covers all genetically modified rats that model lymphocyte proliferation, autoimmune disease or inflammatory disease, including all genetically modified rats with dysfunction in macrophages, immunoglobulin, T-cells, B-cells and/or NK-cells. The patent further covers any assay that screens for potentially useful therapeutic compounds using cells derived from the genetically modified rats. "This patent, and other imminent patents that cover genetically modified rat models of cancer and other diseases, cements Transposagen's position as a premier provider of custom genetically modified rodents," said Eric Ostertag, M.D., Ph.D., President & CEO of Transposagen. "We are proud to be the sole provider of valuable research reagents, such as the hyperactive piggyBacTM transposase and rat models of inflammatory disease, to the research community."

Please see piggyBacTM for more information, as well as Disease Model Partnering Strategy for opportunities in rodent model creation.

About Transposagen Biopharmaceuticals:

Transposagen Biopharmaceuticals, Inc. is a worldwide leader in technologies and services for genetic modification. Transposagen specializes in gene editing tools and custom cell line and animal model creation. To learn more, please visit: http://transposagenbio.com/

Media Contact: Jack Crawford, Transposagen Biopharmaceuticals, (315) 351-9115, jcrawford@transposagenbio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Transposagen Biopharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Transposagen Receives Over $4.3M in Grants and Investment
2. Enbrel® (etanercept) Patent Issued
3. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
4. 12th U.S. Patent Issued To Dyadic International
5. Stemedica Issued U.S. Patent For Stem Cell Treatment of Diabetic Retinopathy and Diabetic Optic Neuropathy
6. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
7. Stemedica Issued U.S. Patent For Ectodermal Stem Cells
8. PharmaDirections is Co-inventor on Second Issued Formulation Patent Entitled “Layered Pharmaceutical Formulations”
9. PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756
10. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
11. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on ... of Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ... is expected to deliver therapeutic levels of olanzapine for a period of 3 months., ...
(Date:2/24/2017)... SAN DIEGO , Feb. 24, 2017  Aethlon ... the following note authored by its Chairman and CEO, ... address at the Munich Security Conference last Saturday, ... engineered virus could kill more people than nuclear weapons. ... by U.S. and U.K. intelligence agencies, that scientific terrorists ...
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: ... of cord blood collection, laboratory testing, hematopoietic stem cell ... unaudited financial results for the third quarter and first ... 2016. Third Quarter of Fiscal 2017 Highlights ... fiscal 2017 increased by 18.6% to RMB200.9 million ($28.9 ...
(Date:2/24/2017)... Corporation (NASDAQ: VWR), the leading global independent provider of product ... its financial results for the fourth quarter and full year ... 4Q16 record quarterly net sales of $1.13 billion, up ... 4Q16 EMEA-APAC segment net sales increased ... net sales increased 2.5%, or down 0.9% on an organic ...
Breaking Biology Technology:
(Date:2/9/2017)... , Feb. 9, 2017 The biomass boiler ... of the biomass boiler market globally in terms of ... biomass boilers. The market for biomass boilers has been ... end-user, application, and country/region. The market based on feedstock ... forest residues, biogas & energy crops, urban residues, and ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/8/2017)... , Feb. 7, 2017 The ... largely by the confluence of organizations, desires to ... for knowledge-based systems (password and challenge questions), biometrics ... and government systems. The market is driven by ... demarcation between consumer and enterprise uses cases, with ...
Breaking Biology News(10 mins):